BioGaia AB (BIOGY)
11.50
0.00 (0.00%)
USD |
OTCM |
Jul 02, 16:00
BioGaia Enterprise Value: 1.012B for July 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 02, 2024 | 1.012B |
| July 01, 2024 | 1.012B |
| June 28, 2024 | 1.012B |
| June 27, 2024 | 1.070B |
| June 26, 2024 | 1.070B |
| June 21, 2024 | 1.070B |
| June 20, 2024 | 1.070B |
| June 18, 2024 | 1.070B |
| June 17, 2024 | 1.070B |
| June 14, 2024 | 1.070B |
| June 13, 2024 | 1.070B |
| June 12, 2024 | 1.070B |
| June 11, 2024 | 1.070B |
| June 10, 2024 | 1.070B |
| June 07, 2024 | 1.070B |
| June 06, 2024 | 1.070B |
| June 05, 2024 | 1.070B |
| June 04, 2024 | 1.070B |
| June 03, 2024 | 1.070B |
| May 31, 2024 | 1.070B |
| May 30, 2024 | 1.070B |
| May 29, 2024 | 1.035B |
| May 28, 2024 | 1.035B |
| May 24, 2024 | 1.012B |
| May 23, 2024 | 1.012B |
| Date | Value |
|---|---|
| May 22, 2024 | 1.012B |
| May 21, 2024 | 1.012B |
| May 20, 2024 | 1.012B |
| May 17, 2024 | 1.012B |
| May 16, 2024 | 1.012B |
| May 15, 2024 | 1.012B |
| May 14, 2024 | 1.012B |
| May 13, 2024 | 1.012B |
| May 10, 2024 | 1.012B |
| May 09, 2024 | 1.012B |
| May 08, 2024 | 1.012B |
| May 07, 2024 | 1.012B |
| May 06, 2024 | 832.16M |
| May 03, 2024 | 832.16M |
| May 02, 2024 | 832.16M |
| May 01, 2024 | 832.16M |
| April 30, 2024 | 832.16M |
| April 29, 2024 | 832.16M |
| April 26, 2024 | 832.16M |
| April 25, 2024 | 832.16M |
| April 24, 2024 | 832.16M |
| April 23, 2024 | 832.16M |
| April 22, 2024 | 832.16M |
| April 19, 2024 | 832.16M |
| April 18, 2024 | 832.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
559.80M
Minimum
May 18 2022
1.497B
Maximum
May 26 2022
863.56M
Average
848.10M
Median
Jan 03 2024
Enterprise Value Benchmarks
| Abliva AB | 10.57M |
| Karolinska Development AB | 62.17M |
| Calliditas Therapeutics AB | 1.056B |
| Oncopeptides AB | -- |
| Olink Holding AB | 3.090B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.75M |
| Revenue (Quarterly) | 35.65M |
| Total Expenses (Quarterly) | 21.85M |
| EPS Diluted (Quarterly) | 0.1167 |
| Gross Profit Margin (Quarterly) | 71.89% |
| Profit Margin (Quarterly) | 32.95% |
| Earnings Yield | 3.04% |
| Operating Earnings Yield | 3.56% |
| Normalized Earnings Yield | 3.040 |